Sage triggers another burst of investor enthusiasm as oral depression drug scores in PhII
Sage Therapeutics shares are once again rocketing up this morning, this time based on positive results from a small Phase II study of an oral version of their depression therapy.
Long one of the most volatile stocks in biotech, Sage says that SAGE-217 clearly hit the goal post for statistical significance in major depressive disorder, achieving a 64% success rate in achieving clinical remission on a commonly used score for depression against 23% on a placebo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
